ONC

#402
BeOne Medicines Ltd. American Depositary Shares
310.0000 USD
+1.43%
Settore:
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
310.0000
310.0000
Intervallo Annuale
271.4701
385.2200
Variazione giornaliera
+1.43%
Variazione Mensile
+8.35%
Variazione di 6 mesi
-1.81%
Variazione Annuale
-1.81%
Chiusura Precedente
305.6400
Apertura
310.0000
Bid
Ask
Minimo
310.0000
High
310.0000
Volume
89
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore 202020212022202320242025 TTM

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.